Healthcare
Angiex, Inc. – SUCCESS PAGE – December 10, 2024
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ to make cancer less lethal.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ to make cancer less lethal.
The company’s AI-powered drug development program has the potential to treat multiple CNS diseases and impact millions of lives.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ to make cancer less lethal.
The company’s AI-powered drug development program has the potential to treat multiple CNS diseases and impact millions of lives.
A clinical-stage biotechnology company pioneering an Intestinal Microbiota Transplant (IMT) platform designed to transform patients’ lives.
A clinical-stage biotechnology company pioneering an Intestinal Microbiota Transplant (IMT) platform designed to transform patients’ lives.
First-in-industry devices to optimize cancer therapies and address infectious disease disorders that are not treatable with drugs
The world-class antibody engineers at OncoOne are creating monoclonal antibodies to treat diseases with exacting specificity and precision
First-in-industry devices to optimize cancer therapies and address infectious disease disorders that are not treatable with drugs
The world-class antibody engineers at OncoOne are creating monoclonal antibodies to treat diseases with exacting specificity and precision
Direct Biologics is a clinical-stage biotech innovator that is harnessing signaling molecules to reduce overactive inflammatory response
Direct Biologics is a clinical-stage biotech innovator that is harnessing signaling molecules to reduce overactive inflammatory response